Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Walloon Cell Therapy Platform for mass production

As the foundation for the new Walloon Cell Therapy Platform begins to set in Gosselies, Wallonia gets excited about this new development. The plat…


IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Challenges for the cell therapy industry

In an exclusive interview, Hugues Bultot, Chief Executive Officer of MaSTherCell, an emerging pioneer in the industrialization of cell-based thera…

POPULAR TAGS

Continued coverage of Celyad's Patent assured

Written by DS on in the category news with the tags , , .


Celyad announced today that the U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR.

“We are pleased with the outcome of this re-examination of our patent related to the production of allogeneic TCR-deficient CAR-T cells. This marks the third decision by the USPTO to uphold this patent, which thus remains valid and enforceable, and provides for continued intellectual property protection for this valuable asset," says Philippe Dechamps, Chief Legal Officer of Celyad.

“Allogeneic CAR T-cells are a promising avenue to broaden the scope of application of cell based immunotherapy”, says Georges Rawadi, VP Business Development and IP of Celyad.  “We look forward to the further development of our own allogeneic programs and also continue to offer other parties access to this important patent to advance the field more broadly.”

Celyad’s U.S. patent (No. 9,181,527), and more precisely claim 1 of the said patent, was challenged by an anonymous third party through an Ex Parte Re-examination procedure. The request for Ex Parte re-examination was filed on February 10th, 2016 and an order granting Ex Parte Re-examination of claim 1 was issued by the USPTO on March 24th, 2016. The final decision of this Ex Parte procedure that was issued on January 6th 2017 is not subject to appeal and upholds the validity of the patent.

Therefore, Celyad’s U.S. patent (No. 9,181,527), confirms continued coverage of CAR-expressing human T-cells, according to Claim 1, modified to reduce or eliminate T-cell receptor expression or function.

You might also like: CAR-T: the T-cell training program to fight cancer
Read more about Celyad 

 

RELATED ARTICLES
Walloon Cell Therapy Platform for mass production

As the foundation for the new Walloon Cell Therapy Platform begins to set in Gosselies, Wallonia gets excited about this new development. The plat…


IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Challenges for the cell therapy industry

In an exclusive interview, Hugues Bultot, Chief Executive Officer of MaSTherCell, an emerging pioneer in the industrialization of cell-based thera…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Biowin UGent Janssen Flanders.bio V-Bio Ventures XpandInnovation GSK Turnstone Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.